CZ253395A3 - Method of controlled activation and degradation of factor vii during purification process - Google Patents

Method of controlled activation and degradation of factor vii during purification process Download PDF

Info

Publication number
CZ253395A3
CZ253395A3 CZ952533A CZ253395A CZ253395A3 CZ 253395 A3 CZ253395 A3 CZ 253395A3 CZ 952533 A CZ952533 A CZ 952533A CZ 253395 A CZ253395 A CZ 253395A CZ 253395 A3 CZ253395 A3 CZ 253395A3
Authority
CZ
Czechia
Prior art keywords
fvii
buffer
nacl
activation
degradation
Prior art date
Application number
CZ952533A
Other languages
Czech (cs)
English (en)
Inventor
Tony Jorgensen
Anders H Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CZ253395A3 publication Critical patent/CZ253395A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Catalysts (AREA)
CZ952533A 1993-03-31 1994-03-24 Method of controlled activation and degradation of factor vii during purification process CZ253395A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93382A DK38293D0 (da) 1993-03-31 1993-03-31 Fremstilling af proteiner

Publications (1)

Publication Number Publication Date
CZ253395A3 true CZ253395A3 (en) 1996-01-17

Family

ID=8092871

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ952533A CZ253395A3 (en) 1993-03-31 1994-03-24 Method of controlled activation and degradation of factor vii during purification process

Country Status (16)

Country Link
US (1) US5700914A (2)
EP (1) EP0691984A1 (2)
JP (1) JPH08508264A (2)
CN (1) CN1039231C (2)
AU (1) AU677309B2 (2)
CA (1) CA2159313A1 (2)
CZ (1) CZ253395A3 (2)
DK (1) DK38293D0 (2)
FI (1) FI954649L (2)
HU (1) HUT72712A (2)
IL (1) IL109164A0 (2)
NO (1) NO953883L (2)
PL (1) PL310887A1 (2)
TW (1) TW278079B (2)
WO (1) WO1994022905A1 (2)
ZA (1) ZA941956B (2)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
RU2364626C2 (ru) * 2003-03-18 2009-08-20 Ново Нордиск Хелт Кэр Аг Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
EP1711513B1 (en) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration of factor vii solutions to remove virus
RU2373953C2 (ru) * 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
ES2395544T3 (es) * 2004-12-23 2013-02-13 Novo Nordisk Health Care Ag Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés
ES2349112T3 (es) * 2005-01-14 2010-12-28 Bayer Healthcare Llc Método de purificación de factor vii.
PL1907540T3 (pl) * 2005-07-22 2013-05-31 Bayer Healthcare Llc Aktywacja czynnika VII w roztworze
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101384272B (zh) * 2005-12-20 2013-05-01 杜克大学 用于递送具有增强的药理性质的活性剂的方法和组合物
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
CN104736133B (zh) 2012-10-17 2020-07-10 宝洁公司 用于递送口腔护理活性物质的条带以及施用口腔护理活性物质的方法
ES2906118T3 (es) * 2016-12-22 2022-04-13 Km Biologics Co Ltd Método cromatográfico para recolectar factor VII de coagulación sanguínea con alto rendimiento

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Also Published As

Publication number Publication date
US5700914A (en) 1997-12-23
HU9502846D0 (en) 1995-12-28
NO953883L (no) 1995-11-28
NO953883D0 (no) 1995-09-29
HUT72712A (en) 1996-05-28
FI954649A0 (fi) 1995-09-29
FI954649A7 (fi) 1995-09-29
FI954649L (fi) 1995-09-29
ZA941956B (en) 1994-09-30
AU6423994A (en) 1994-10-24
CA2159313A1 (en) 1994-10-13
AU677309B2 (en) 1997-04-17
WO1994022905A1 (en) 1994-10-13
JPH08508264A (ja) 1996-09-03
DK38293D0 (da) 1993-03-31
IL109164A0 (en) 1994-06-24
CN1121723A (zh) 1996-05-01
TW278079B (2) 1996-06-11
EP0691984A1 (en) 1996-01-17
CN1039231C (zh) 1998-07-22
PL310887A1 (en) 1996-01-08

Similar Documents

Publication Publication Date Title
CZ253395A3 (en) Method of controlled activation and degradation of factor vii during purification process
AU740753C (en) Improved methods for processing activated protein C
Wasley et al. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway.
Stenflo Structure and function of protein C
US20080214462A1 (en) FIX-Mutant Proteins for Hemophilia B Treatment
Josic et al. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C
AU2008209986A1 (en) FVIII-independent FIX-mutant proteins for hemophilia A treatment
PL191778B1 (pl) Analog czynnika X Δ , rekombinowany kwas nukleinowy, wektor, komórka, kompozycje i ich zastosowania oraz sposób wytwarzania kompozycji
US6958322B1 (en) Factor X analog with an improved ability to be activated
RU2167936C2 (ru) Способ минимизации деградации активированного протеина с (варианты), стабилизированная композиция активированного протеина с
US5510248A (en) Stable recombinant meizothrombin-like polypeptides
AU769144B2 (en) Improved methods for processing activated protein C
AU4409399A (en) Human protein c polypeptide
CZ373799A3 (cs) Zlepšené způsoby zpracování aktivovaného proteinu C
Hung Structural-functional Studies of the Non-enzymatic Domains of Prothrombin
Carter Structural-Functional Relationships in the Human Thrombin A-Chain
Su Localization of ligand-binding exosites in the catalytic domain of FXIa and determination of the roles of calcium and the heavy chain of FXIa in fix activation by FXIa
EP1557463A1 (en) Improved methods for processing activated protein C
Boskovic Studies of prothrombinase-catalyzed activation of bovine prothrombin.
SK124699A3 (en) Activated vitamin k-dependent blood factor and method for the production thereof
HK1219285A1 (en) Purification method for vitamin k dependent proteins by anion exchange chromatography
HK1219285B (en) Purification method for vitamin k dependent proteins by anion exchange chromatography